Drug
Discovery &
Development
Biocon's
Syngene in Research
Pact with Bristol-Myers
Squibb
Biocon
Ltd announced
that its subsidiary,
Syngene International
Pvt Ltd, has entered
into a research
partnership with
Bristol-Myers
Squibb to provide
research and development
services for discovery
and early drug
development.
This alliance
would help Bristol-Myers
Squibb to significantly
enhance its existing
relationship with
Biocon's Syngene
to further develop
integrated capabilities
in India in medicinal
chemistry, biology,
drug metabolism
and pharmaceutical
development.
As per the deal,
Syngene will partner
with Bristol-Myers
Squibb through
a dedicated research
facility at Biocon
Park, Bangalore.
It would house
more than 400
scientists in
this center to
help advance Bristol-Myers
Squibb's discovery
and early drug
development.
The Bangalore-based
company disclosed
that the alliance
aims to provide
cost-effective
growth and access
to top scientific
talent in India,
utilizing the
current global
demand for bio-partnering.
Biocon recently
released five
renal therapy
drugs, which are
priced 35-40 percent
lesser than those
available in the
market. The new
immunosuppressants
drugs for renal
therapy include
Ranodapt, Tacrograf,
Cyclophil ME,
Rapacan and Erypro.
Immunosuppressants
are medicines
that inhibit or
prevent the activity
of the body's
immune system.
Syngene International
Pvt Ltd is an
internationally
reputed Customs
Research company
with multi-disciplinary
skills in synthetic
chemistry and
molecular biology,
microbial genomics
and informatics,
provides customized
research and development
to leading names
worldwide.
Established in
1978, Biocon Ltd
is one of India's
premier biotechnology
companies. Biocon
and its two subsidiaries,
Syngene International
Pvt Ltd and Clinigene
International
Pvt Ltd, form
a fully integrated
biotechnology
enterprise specializing
in biopharmaceuticals,
custom research,
clinical research
and enzymes. With
successful initiatives
in drug discovery,
clinical development,
bioprocessing
and global marketing,
the company delivers
products and solutions
to partners and
customers across
50 countries
Biocon posted
a net profit of
Rs. 174 crore
on total income
of Rs. 793 crores
during the financial
year ended March
31, 2006.
